Exclusive Agreement with a South Korean Biomaterials Company on Joint Development and Marketing Rights of BMP-2 Formulation in Japan

August 11,2020

Nippon Zoki Pharmaceutical Co., Ltd.* announced that it has reached an agreement with CG Bio Inc. on exclusive joint development and marketing rights in Japan of bone morphogenetic protein-2 (BMP-2) formulation NOVOSIS Putty, whose patent rights, etc. are held by the South Korean regenerative medicine specialist.

Widely approved in North America and Europe, BMP-2 formulation has become an established tool for the treatment of lumbar spine degeneration, but its development in Japan has been slow at best. After a briefing by Dr. Daisuke Sakai, a scientific advisor of TUNZ Pharma, on the necessity of the product for the treatment of a lumbar spine degenerative disease, TUNZ Pharma began discussions with CG Bio on the possible development of the formulation in Japan. The agreement has already been hailed by many orthopedic clinicians, who eagerly await its early launch in the country. TUNZ Pharma will advance the development of this product with professional input from Dr. Sakai.

*TUNZ Pharma Co., Ltd. is an affiliate of Nippon Zoki Pharmaceutical Co., Ltd.

<Click here for the media article on this news (in Japanese only)>
Nikkan Yakugyo October 2, 2019 Issue [License no.: 20200812_01]
Use of the article authorized by Jiho, Inc.